{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:28:40Z","timestamp":1777624120079,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2018007"],"award-info":[{"award-number":["2018007"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2016097"],"award-info":[{"award-number":["2016097"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40263-021-00847-4","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T17:04:03Z","timestamp":1629479043000},"page":"999-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-4941","authenticated-orcid":false,"given":"Lennart","family":"Kylles\u00f8","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-7076","authenticated-orcid":false,"given":"Robert L\u00f8vsletten","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1204-787X","authenticated-orcid":false,"given":"\u00d8ystein","family":"Karlstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-3568","authenticated-orcid":false,"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-2751","authenticated-orcid":false,"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"5","key":"847_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020141","volume":"2","author":"S Saha","year":"2005","unstructured":"Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5): e141. https:\/\/doi.org\/10.1371\/journal.pmed.0020141.","journal-title":"PLoS Med"},{"issue":"1\u20133","key":"847_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2008.01.022","volume":"10","author":"R Tandon","year":"2008","unstructured":"Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, \u201cJust the Facts\u201d: what we know in 2008 part 1: overview. Schizophr Res. 2008;10(1\u20133):4\u201319. https:\/\/doi.org\/10.1016\/j.schres.2008.01.022.","journal-title":"Schizophr Res"},{"key":"847_CR3","unstructured":"World Health Organization. World report on disability. World Health Organization. 2011. https:\/\/www.who.int\/disabilities\/world_report\/2011\/report.pdf. Accessed 26 Mar 2020."},{"issue":"3","key":"847_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174(3):216\u201329. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503.","journal-title":"Am J Psychiatry"},{"key":"847_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/pgpm.S115741","volume":"9","author":"J Lally","year":"2016","unstructured":"Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med. 2016;9:117\u201329. https:\/\/doi.org\/10.2147\/pgpm.S115741.","journal-title":"Pharmgenomics Pers Med."},{"issue":"2","key":"847_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40263-016-0311-1","volume":"30","author":"J Nielsen","year":"2016","unstructured":"Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. Worldwide differences in regulations of clozapine use. CNS Drugs. 2016;30(2):149\u201361. https:\/\/doi.org\/10.1007\/s40263-016-0311-1.","journal-title":"CNS Drugs"},{"issue":"9896","key":"847_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)60733-3.","journal-title":"Lancet"},{"key":"847_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiat. 2019;76:1052\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1702.","journal-title":"JAMA Psychiat"},{"issue":"10202","key":"847_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3.","journal-title":"Lancet"},{"key":"847_CR10","doi-asserted-by":"publisher","unstructured":"Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. Schizophr Bull. 2018;45(2):315-29. doi:https:\/\/doi.org\/10.1093\/schbul\/sby052.","DOI":"10.1093\/schbul\/sby052"},{"issue":"12","key":"847_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323. https:\/\/doi.org\/10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"issue":"1","key":"847_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1055\/s-0034-1394397","volume":"48","author":"FA Mustafa","year":"2015","unstructured":"Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. \u201cSchizophrenia past clozapine\u201d: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry. 2015;48(1):11\u20134. https:\/\/doi.org\/10.1055\/s-0034-1394397.","journal-title":"Pharmacopsychiatry"},{"key":"847_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00944-5","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Kuzin M, Kane JM, Hiemke C, Paulzen M, Haen E. Elevated clozapine concentrations in clozapine-treated patients with hypersalivation. Clin Pharmacokinet. 2020. https:\/\/doi.org\/10.1007\/s40262-020-00944-5.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20133","key":"847_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","volume":"174","author":"SE Legge","year":"2016","unstructured":"Legge SE, Hamshere M, Hayes RD, Downs J, O\u2019Donovan MC, Owen MJ, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1\u20133):113\u20139. https:\/\/doi.org\/10.1016\/j.schres.2016.05.002.","journal-title":"Schizophr Res"},{"issue":"6","key":"847_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):603\u201313. https:\/\/doi.org\/10.4088\/JCP.12r08064.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"847_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","volume":"62","author":"D Siskind","year":"2017","unstructured":"Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772\u20137. https:\/\/doi.org\/10.1177\/0706743717718167.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"847_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1176\/ajp.148.2.231","volume":"148","author":"PJ Perry","year":"1991","unstructured":"Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148(2):231\u20135. https:\/\/doi.org\/10.1176\/ajp.148.2.231.","journal-title":"Am J Psychiatry"},{"key":"847_CR18","unstructured":"Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55 Suppl B:117-21."},{"issue":"1\u201302","key":"847_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"847_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/01.jcp.0000095351.32154.3a","volume":"23","author":"MC Mauri","year":"2003","unstructured":"Mauri MC, Volonteri LS, Dell\u2019Osso B, Regispani F, Papa P, Baldi M, et al. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. 2003;23(6):660\u20134. https:\/\/doi.org\/10.1097\/01.jcp.0000095351.32154.3a.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"847_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3109\/00048679809068332","volume":"32","author":"R Bell","year":"1998","unstructured":"Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 1998;32(4):567\u201374. https:\/\/doi.org\/10.3109\/00048679809068332.","journal-title":"Aust N Z J Psychiatry"},{"issue":"5","key":"847_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1046\/j.1365-2125.1997.t01-1-00606.x","volume":"44","author":"M Jerling","year":"1997","unstructured":"Jerling M, Merle Y, Mentre F, Mallet A. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44(5):447\u201353. https:\/\/doi.org\/10.1046\/j.1365-2125.1997.t01-1-00606.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"847_CR23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1021\/tx100131f","volume":"23","author":"S Dragovic","year":"2010","unstructured":"Dragovic S, Boerma JS, van Bergen L, Vermeulen NP, Commandeur JN. Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine. Chem Res Toxicol. 2010;23(9):1467\u201376. https:\/\/doi.org\/10.1021\/tx100131f.","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"847_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1124\/dmd.112.050484","volume":"41","author":"S Dragovic","year":"2013","unstructured":"Dragovic S, Gunness P, Ingelman-Sundberg M, Vermeulen NP, Commandeur JN. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013;41(3):651\u20138. https:\/\/doi.org\/10.1124\/dmd.112.050484.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"847_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/00912700122010717","volume":"41","author":"OV Olesen","year":"2001","unstructured":"Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41(8):823\u201332. https:\/\/doi.org\/10.1177\/00912700122010717.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"847_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","volume":"28","author":"CF Thorn","year":"2018","unstructured":"Thorn CF, Muller DJ, Altman RB, Klein TE. PharmGKB summary: clozapine pathway, pharmacokinetics. Pharmacogenet Genomics. 2018;28(9):214\u201322. https:\/\/doi.org\/10.1097\/FPC.0000000000000347.","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"847_CR27","first-page":"243","volume":"328","author":"MW Jann","year":"1994","unstructured":"Jann MW, Lam YW, Chang WH. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch Int Pharmacodyn Ther. 1994;328(2):243\u201350.","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"5","key":"847_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/s0278-5846(98)00035-9","volume":"22","author":"WH Chang","year":"1998","unstructured":"Chang WH, Lin SK, Lane HY, Wei FC, Hu WH, Lam YW, et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22(5):723\u201339. https:\/\/doi.org\/10.1016\/s0278-5846(98)00035-9.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"847_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","volume":"38","author":"L Bertilsson","year":"1994","unstructured":"Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994;38(5):471\u20133. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04385.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"847_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","volume":"97","author":"MS Faber","year":"2005","unstructured":"Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol. 2005;97(3):125\u201334. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_973160.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"847_CR31","unstructured":"National Institute of Health and Care Excellence (NICE). Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition. 2014. https:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133. Accessed 6 May 2021."},{"key":"847_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.euroneuro.2020.06.007","volume":"37","author":"RL Smith","year":"2020","unstructured":"Smith RL, Tveito M, Kylles\u00f8 L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs\u2014a study based on blood sample analyses from 24,239 patients. Eur Neuropsychopharmacol. 2020;37:64\u20139. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.06.007.","journal-title":"Eur Neuropsychopharmacol"},{"key":"847_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2020.11.025","author":"RL Smith","year":"2020","unstructured":"Smith RL, Tveito M, Kylles\u00f8 L, Jukic MM, Ingelman-Sundberg M, Andreassen OA, et al. Rates of complete nonadherence among atypical antipsychotic drugs: a study using blood samples from 13,217 outpatients with psychotic disorders. Schizophr Res. 2020. https:\/\/doi.org\/10.1016\/j.schres.2020.11.025.","journal-title":"Schizophr Res"},{"key":"847_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/PGPM.S142314","volume":"10","author":"I Piatkov","year":"2017","unstructured":"Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10:235\u201342. https:\/\/doi.org\/10.2147\/PGPM.S142314.","journal-title":"Pharmgenomics Pers Med."},{"issue":"1","key":"847_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","volume":"24","author":"A Rostami-Hodjegan","year":"2004","unstructured":"Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24(1):70\u20138. https:\/\/doi.org\/10.1097\/01.jcp.0000106221.36344.4d.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"847_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/jcp.0000000000001202","volume":"40","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Kane JM, de Leon J. Adding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature review. J Clin Psychopharmacol. 2020;40(3):308\u201310. https:\/\/doi.org\/10.1097\/jcp.0000000000001202.","journal-title":"J Clin Psychopharmacol"},{"key":"847_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","volume":"210","author":"M Augustin","year":"2019","unstructured":"Augustin M, Schoretsanitis G, Pfeifer P, Grunder G, Liebe C, Paulzen M. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res. 2019;210:143\u20138. https:\/\/doi.org\/10.1016\/j.schres.2019.05.033.","journal-title":"Schizophr Res"},{"issue":"5","key":"847_CR38","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3109\/09540261.2013.836475","volume":"25","author":"G Hefner","year":"2013","unstructured":"Hefner G, Laib AK, Sigurdsson H, Hohner M, Hiemke C. The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. Int Rev Psychiatry. 2013;25(5):494\u2013508. https:\/\/doi.org\/10.3109\/09540261.2013.836475.","journal-title":"Int Rev Psychiatry"},{"issue":"3","key":"847_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","volume":"19","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Paulzen M, Unterecker S, Schwarz M, Conca A, Zernig G, et al. TDM in psychiatry and neurology: a comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018;19(3):162\u201374. https:\/\/doi.org\/10.1080\/15622975.2018.1439595.","journal-title":"World J Biol Psychiatry."},{"key":"847_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.05.033","author":"J de Leon","year":"2019","unstructured":"de Leon J. Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics. Neuropharmacology. 2019. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.05.033.","journal-title":"Neuropharmacology"},{"key":"847_CR41","unstructured":"Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 12th ed. ed. Wiley-Blackwell; 2015."},{"issue":"12","key":"847_CR42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","volume":"62","author":"T Haslemo","year":"2006","unstructured":"Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62(12):1049\u201353. https:\/\/doi.org\/10.1007\/s00228-006-0209-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"847_CR43","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40263-017-0469-1","volume":"31","author":"RL Smith","year":"2017","unstructured":"Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, et al. Correlation between serum concentrations of n-desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study. CNS Drugs. 2017;31(11):991\u20137. https:\/\/doi.org\/10.1007\/s40263-017-0469-1.","journal-title":"CNS Drugs"},{"issue":"3","key":"847_CR44","doi-asserted-by":"publisher","first-page":"e004216","DOI":"10.1136\/bmjopen-2013-004216","volume":"4","author":"Y Tsuda","year":"2014","unstructured":"Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3):e004216. https:\/\/doi.org\/10.1136\/bmjopen-2013-004216.","journal-title":"BMJ Open"},{"issue":"2","key":"847_CR45","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","volume":"30","author":"M Valenstein","year":"2004","unstructured":"Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255\u201364.","journal-title":"Schizophr Bull"},{"issue":"3","key":"847_CR46","first-page":"1463","volume":"275","author":"JL Maggs","year":"1995","unstructured":"Maggs JL, Williams D, Pirmohamed M, Park BK. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995;275(3):1463\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"847_CR47","first-page":"1375","volume":"283","author":"DP Williams","year":"1997","unstructured":"Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther. 1997;283(3):1375\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"847_CR48","first-page":"1476","volume":"275","author":"ZC Liu","year":"1995","unstructured":"Liu ZC, Uetrecht JP. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther. 1995;275(3):1476\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"847_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.psychres.2019.01.110","volume":"275","author":"A Ucok","year":"2019","unstructured":"Ucok A, Ya\u011fc\u0131o\u011flu EA, Y\u0131ld\u0131z M, Kaymak SU, Saka MC, Ta\u015fdelen R, et al. Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. Psychiatry Res. 2019;275:149\u201354. https:\/\/doi.org\/10.1016\/j.psychres.2019.01.110.","journal-title":"Psychiatry Res"},{"issue":"1","key":"847_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/acps.12233","volume":"130","author":"MC Davis","year":"2014","unstructured":"Davis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014;130(1):30\u20139. https:\/\/doi.org\/10.1111\/acps.12233.","journal-title":"Acta Psychiatr Scand"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00847-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00847-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00847-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T12:58:53Z","timestamp":1630414733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00847-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["847"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00847-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"15 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by University of Oslo (incl Oslo University Hospital). This work was supported by the South-Eastern Norway Regional Health Authority (grant numbers 2018007 to Lennart Kylles\u00f8 and 2016097 to Robert L. Smith).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ole A. Andreassen has received speaker\u00b4s honorarium from Lundbeck and Sunovion and has been a consultant to HealthLytix. Lennart Kylles\u00f8, Robert L. Smith, \u00d8ystein Karlstad and Espen Molden have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics and the Hospital Investigational Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available because of privacy and ethical restrictions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All authors were involved in the ideation, conceptualizing and design of the study. LK and RLS collected and prepared the data material. LK, RLS and EM analysed and interpreted the data. LK drafted the manuscript. All other authors critically reviewed the manuscript. All authors saw and approved the submitted version. All authors take accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}